Top Poster Takeaways for Urothelial Carcinoma From The 2026 ESMO Congress
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
At the , 3 posters examined outcomes in advanced urothelial carcinoma. Two exploratory analyses from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856) showed that the overall survival (OS) benefit of frontline enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) over platinum-based chemotherapy held in patients with clinically challenging features. A third poster showed that early deaths still limit how far treatment advances reach patients with metastatic disease.
